Today in Biology — Aug 28

[THEO] Okay, picture this: You're a biologist, you've got a brilliant idea, maybe you've even tinkered a bit with some non-model organisms, and now you need funding. Where do you go? How do you even begin to navigate the landscape of national initiatives and grant programs? Because right now, it feels a bit like the ground is shifting under our feet.

[DR. MARA] Indeed. We're seeing some significant reconfigurations in how science, particularly biology, is being supported and directed at the national level, especially within the US. It's a mix of ambitious new programs and some unsettling changes to established structures.

[THEO] Right, and the biggest, loudest signal right now seems to be coming from the Department of Energy – the DOE. They're making a huge push with something called the Genesis Mission. What is this, exactly?

[DR. MARA] The Genesis Mission is a major, multi-billion-dollar initiative, initially announced during the Trump administration, with a strong focus on artificial intelligence for science. We’re seeing a lot of momentum around it. Most recently, they just held their inaugural Summit, where the Under Secretary for Science, Darío Gil, was a keynote speaker, and Secretary Chris Wright announced the first 278 projects.

[THEO] So, it’s a big AI-for-science play. And the DOE, not NIH or NSF, is taking the lead here. That's a significant pivot, isn't it? For biologists, especially those working on engineering organisms, it means looking at new avenues for funding and collaboration. It suggests a future where computational approaches are not just supportive, but central to experimental design and discovery.

[DR. MARA] Precisely. The DOE’s involvement indicates a focus on large-scale, often infrastructure-heavy projects, leveraging national lab capabilities. For engineering biology, this could mean significant resources for developing AI-driven platforms for organism design, synthetic pathway optimization, or even environmental remediation strategies. It's about scaling up and accelerating discovery through computational power.

[THEO] And that’s a direct response to, let's call it, the 'AI moment' we're in. We've seen some chatter online, for instance, about how AI methods are starting to match human experts in tasks like designing RNA pseudoknots on citizen science platforms like Eterna. It’s a real demonstration of AI's growing capability in molecular design.

[DR. MARA] That specific example, with RNA folding, highlights the power of AI to explore vast sequence spaces and predict stable structures, which is incredibly relevant for engineering new biological functions. But while the Genesis Mission is expanding, we're also seeing contractions elsewhere.

[THEO] This is where things get a bit more... tense, I think, for many researchers. The National Science Foundation, the NSF, is making some big structural changes and facing budget constraints.

[DR. MARA] Indeed. There's been a significant reorganization within the NSF. For example, they've dissolved divisions that biologists had targeted for decades. The BIO Core program, a substantial $280 million initiative supporting 250-300 awards, is now structured in a way that, as some are noting, lacks clear program targets. This makes it harder for researchers to identify where their work fits and how to apply.

[THEO] So, if you've been working in a particular niche for years, relying on a specific NSF division, suddenly that pathway might be gone. It's a lot of uncertainty. And on top of that, there's been reporting that the NSF is set to issue the lowest number of new grants in four decades. That's a serious headwind for basic science, isn't it?

[DR. MARA] It is. Fewer new grants mean fewer opportunities for early-career researchers, less exploratory science, and increased competition across the board. While new initiatives like Genesis are exciting, they don't fully offset the impact on foundational research often supported by the NSF. It forces biologists to adapt their research programs or seek out alternative funding sources.

[THEO] Yet, even within the NSF, there are still targeted investments, right? I saw they renewed a quantum leap challenge institute with a significant investment in quantum sensing for biology.

[DR. MARA] Yes, that's a notable exception and points to strategic areas of investment. $37.5 million for quantum sensing in biology indicates a focus on developing cutting-edge tools for measurement and observation at the molecular level, which could revolutionize how we understand and manipulate biological systems. It’s about pushing the boundaries of what we can detect.

[THEO] So, on one hand, a huge push into AI-driven biology with the DOE’s Genesis Mission, signaling a new era of large-scale, computationally intensive science. On the other, the NSF is consolidating, re-organizing, and facing budget pressures, which means fewer grants for traditional basic research. It feels like a moment of both immense opportunity and significant challenge for the life sciences.

[DR. MARA] It's a period of significant strategic realignment, certainly. Researchers need to be keenly aware of these shifts to effectively navigate the funding landscape and position their work for impact.

[THEO] Absolutely. A lot to keep an eye on as these initiatives mature. And that brings us to the end of our briefing for today.